Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors

  • Sirianong Namwongprom
  • Franklin C. Wong
  • Ukihide Tateishi
  • Edmund E. Kim
  • Sombut Boonyaprapa
Original Article



Chromogranin A (CgA) has been gaining acceptance as a helpful tumor marker in patients with neuroendocrine tumors, with respect to both diagnosis and prognosis. The objective of this study was to correlate serum CgA levels and somatostatin receptor scintigraphy (SRS) findings in the evaluation of metastases in carcinoid tumors.

Materials and methods

A total of 125 patients(61 men and 64 women, aged from 23 to 84 years) with histologically diagnosed carcinoid tumor underwent serum CgA assay and SRS for detecting metastasis or disease recurrence. The quantitative determination of CgA was performed in serum using an enzyme immunoassay with a cut-off value fixed at 39 U/l. Scintigraphies were performed with 200–220 MBq of In-111-DTPA-Phel-octreotide including whole-body images as well as single-photon emission computed tomography and computed tomography scans of the chest and abdomen.


The primary tumors originated from the gastrointestinal tract in 115 of 125 patients (92.0%), the lung in 7 of 125 patients (5.6%), the kidney in 2 of 125 patients (1.6%), and the breast in 1 of 125 patients (0.8%). The primary tumors originated from the foregut, midgut, and hindgut in 13.6%, 71.2%, and 12.8%, respectively. Correlation of SRS with other imaging modalities and clinical follow-up findings revealed a sensitivity, a specificity, and an accuracy of 82.9%, 97.7%, and 88.0%, respectively, and for CgA 62.2%, 83.7%, and 69.6%, respectively. There was 1 false-positive and 14 falsenegative SRS results and 7 false-positive and 31 falsenegative CgA analyses. SRS demonstrated higher sensitivity, specificity, and accuracy than CgA for the evaluation of metastatic carcinoid tumors. The concordance between SRS and CgA results was 67.2%. Discrepancies, such as positive SRS with normal CgA levels, were noted in 26 (20.8%) cases, whereas negative SRS with high CgA levels was seen in 15 (12.0%) cases. Combining the results of CgA and SRS increased the sensitivity (92.7%) but decreased the specificity (81.4%) of tumor detection.


In our study, SRS proved to be more sensitive, more specific, and more accurate than CgA for metastatic evaluation of carcinoid tumors. Positive SRS correlated with elevation of serum CgA levels. Serum CgA might have some diagnostic utility in patients with negative SRS studies. Nevertheless, both SRS and CgA should be considered useful tools in the evaluation of metastases in carcinoid patients.


Somatostatin receptor scintigraphy Chromogranin A Carcinoid tumors 


  1. 1.
    Gilligan CJ, Lawton GP, Tang LH, West AB, Modlin IM. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995;90:338–352.PubMedGoogle Scholar
  2. 2.
    Newton JN, Swerdlow AJ, dos Santos Silva IM, Vessey MP, Grahame-Smith DG, Primatesta P, et al. The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 1994;70:939–942.PubMedGoogle Scholar
  3. 3.
    Modlin M, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813–829.PubMedCrossRefGoogle Scholar
  4. 4.
    Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963;1:238–239.PubMedCrossRefGoogle Scholar
  5. 5.
    Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999;86:858–865.PubMedCrossRefGoogle Scholar
  6. 6.
    Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, et al. Carcinoid tumors: analysis of prognosis factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685–690.PubMedCrossRefGoogle Scholar
  7. 7.
    Angeletti RH. Chromogranins and neuroendocrine secretion. Lab Invest 1986;55:387–390.PubMedGoogle Scholar
  8. 8.
    Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991;12:181–187.PubMedGoogle Scholar
  9. 9.
    Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 1992;49:497–528.PubMedCrossRefGoogle Scholar
  10. 10.
    Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW. Chromogranin A: its clinical value as marker of neuroendocrine tumours (review). Eur J Clin Invest 1998;28:431–440.PubMedCrossRefGoogle Scholar
  11. 11.
    Ferrari L, Seregni E, Bajetta E, Martinetti A, Bombardieri E. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours (review). Anticancer Res 1999;19:3415–3427.PubMedGoogle Scholar
  12. 12.
    Drivsholm L, Paloheimo LI, Osterlind K. Chromogranin A: a significant prognostic factor in small cell lung cancer. Br J Cancer 1999;81:667–671.PubMedCrossRefGoogle Scholar
  13. 13.
    Sobol RE, O’Connor DT, Addison J, Suchocki K, Royston I, Deftos LJ. Elevated serum chromogranin A concentration in small cell lung carcinoma. Ann Intern Med 1986;105:698–700.PubMedGoogle Scholar
  14. 14.
    Kvols LK, Reubi JC. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol 1993;32:197–201.PubMedCrossRefGoogle Scholar
  15. 15.
    Akerstrom G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991;30:547–553.PubMedCrossRefGoogle Scholar
  16. 16.
    Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–731.PubMedCrossRefGoogle Scholar
  17. 17.
    Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853–858.PubMedGoogle Scholar
  18. 18.
    Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997;112:335–347.PubMedCrossRefGoogle Scholar
  19. 19.
    Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002;32:84–91.PubMedCrossRefGoogle Scholar
  20. 20.
    Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455–3459.PubMedGoogle Scholar
  21. 21.
    Benalia N, Gerjoux G, Puente E, Buscail L, Susini C. Somatostatin receptors. Digestion 2000;62Suppl 1:27–32.CrossRefGoogle Scholar
  22. 22.
    Kvols L, Brown M, O’Connor M, Hung JC, Hayostek RJ, Reubi JC, et al. Evaluation of radiolabeled somatostatin analogue (I-123 octreotide) in the detection and localization of carcinoid and islet tumors. Radiology 1993;187:129–133.PubMedGoogle Scholar
  23. 23.
    Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PPM, Lamberts SEJ. Somatostatin analogue scintigraphy in carcinoid tumors. Eur J Nucl Med 1993;20:283–292.PubMedCrossRefGoogle Scholar
  24. 24.
    Lamberts SWJ, Reubi JC, Krenning EP. Validation of somatostatin receptor scintigraphy in the localization of neuroendocrne tumours. Acta Oncol 1993;32:167–170.PubMedCrossRefGoogle Scholar
  25. 25.
    Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al. Chromogranin A as a serum marker for neuroendocrine neoplasia: comparison with neuron-specific-enolase and the α-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82:2622–2628.PubMedCrossRefGoogle Scholar
  26. 26.
    Oberg K. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685–690.PubMedCrossRefGoogle Scholar
  27. 27.
    Seregni D, Ferrari L, Bajetta E, Aartinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001;12Suppl 2:S69–S72.PubMedCrossRefGoogle Scholar
  28. 28.
    Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995;144:49–59.PubMedGoogle Scholar
  29. 29.
    Ganim RB, Norton JA. Recent advances in carcinoid pathogenesis, diagnosis and management. Surg Oncol 2000;9:173–179.PubMedCrossRefGoogle Scholar
  30. 30.
    Seregni E, Ferrari L, Stivanello M, Dogliotti L. Laboratory tests for neuroendocrine tumours. Q J Nucl Med 2000;44:22–41.PubMedGoogle Scholar
  31. 31.
    Baudin D, Bidart JM, Bachelot A, Ducreux M, Elias D, Ruffie P, et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 2001;12Suppl 2:S79–S82.PubMedCrossRefGoogle Scholar
  32. 32.
    O’Connor DT, Pandian MR, Carlton E, Cervenka JH, Hsiao RJ. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 1989;35:1631–1637.PubMedGoogle Scholar
  33. 33.
    Hsiao RJ, Mezger MS, O’Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990;37:955–964.PubMedCrossRefGoogle Scholar
  34. 34.
    Stridsberg M, Husebye ES. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. Eur J Endocrinol 1997;136:67–73.PubMedGoogle Scholar
  35. 35.
    Takiyyuddin MA, Cervenka JH, Hsiao RJ, Barbosa JH, Parmer RJ, O’Connor DT. Chromogranin A: storage and release in hypertension. Hypertension 1990;15:237–246.PubMedGoogle Scholar
  36. 36.
    Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997;32:198–202.PubMedCrossRefGoogle Scholar
  37. 37.
    Sanduleanu S, Stridsberg M, Jonkers D, Hameetemna W, Deimond I, Lundqvist G, et al. Serum gastrin and chromogranin A during meals. Aliment Pharmacol Ther 1999;13:145–153.PubMedCrossRefGoogle Scholar
  38. 38.
    Granberg D, Stridsberg M, Seensalu R, Eriksson B, Lundqvist G, Oberg K, et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999;84:2712–2717.PubMedCrossRefGoogle Scholar
  39. 39.
    Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991;146:358–361.PubMedGoogle Scholar
  40. 40.
    Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerød OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings. Prostate 1997;30:1–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Eriksson B, Arnberg H, Lindgren PG, Lorelius LE, Magnusson A, Lundqvist G, et al. Neuroendocrine pancreatic tumors: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 1990;228:103–113.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2008

Authors and Affiliations

  • Sirianong Namwongprom
    • 1
    • 2
  • Franklin C. Wong
    • 1
  • Ukihide Tateishi
    • 1
  • Edmund E. Kim
    • 1
  • Sombut Boonyaprapa
    • 2
  1. 1.Department of Nuclear MedicineThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Division of Nuclear Medicine, Department of Radiology, Faculty of MedicineChiang Mai UniversityChiang MaiThailand

Personalised recommendations